Back to search

Switzerland· 65291001

Zydelig 100 mg, Filmtabletten

A idelalisib product containing idelalisibum, registered in Switzerland by Gilead Sciences Switzerland Sàrl and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EM01

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedZydelig 100 mg, FilmtablettenATCL01EM01REGISTER NO.65291001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Idelalisib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EM01 (idelalisib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Idelalisib · ATC L01EM01

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of idelalisib costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.

  • Switzerland: $222.92 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Idelalisib · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$222.92
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
idelalisibum
Manufacturer
Gilead Sciences Switzerland Sàrl
Country
Switzerland (CH)
ATC code
L01EM01
ATC class
Idelalisib
Defined daily dose
0.3 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680652910013
    60 Stk
    CHF 3697.5

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

820 interactions on record for idelalisib.

Graded by severity as the source publishes them — 236 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Idelalisib · interactions on record

820 records

  • 236 severe
  • 568 moderate
  • 16 minor

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • LoperamideA07DA03severe
  • BudesonideA07EA06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Idelalisib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All idelalisib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Zydelig
  • Liechtenstein · Zydelig
  • Norway · Zydelig

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ee5a4df3-de05-4ca6-b4eb-4a35a6ef4321
GET /v1/drugs/ee5a4df3-de05-4ca6-b4eb-4a35a6ef4321?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "idelalisibum 100 mg",
  "valid_from": "2020-05-01",
  "limitations": "[{\"description\":\"Die Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nln Kombination mit bis zu acht Zyklen Rituximab und anschliessender Monotherapie bis eine Krankheitsprogression oder inakzeptable Toxizität auftritt zur Behandlung von Patienten mit progressiver, symptomatischer CLL und Komorbidität (schwere Neutropenie oder Thrombozytopenie bedingt durch kumulative Myelotoxizität vorheriger Chemo-Therapien oder eine Kreatininclearance < 60 ml/min oder ein cumulative illness rating scale (CIRS)-Score > 6 oder einem vergleichbaren Wert eines anderen anerkannten Bewertungssystems) ab der zweiten Linie bei Frührezidiven (Rezidiv entsprechend der Vortherapie gemäss Leitlinien bis zu maximal 3 Jahren) oder bei Patienten, die für eine Chemoimmuntherapie nicht geeignet sind.<br>\\nAls Monotherapie zur Behandlung von Patienten mit rezidivierendem follikulärem Lymphom (FL), die zwei vorausgegangene Therapien erhalten haben.<br>\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2020-05-01\"}]",
  "galenic_form": "Filmtabl 100 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2015-05-01",
  "self_retention_pct": 10
}

See everything about idelalisib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.